Skip to main content
Caplight Logo









Vicinitas Therapeutics

Vicinitas Therapeutics

Private
South San Francisco, CaliforniaHealthcare & Life Scienceshttps://vicinitastx.com/

Last Round

Series A

Jul 28, 2022

Total Funding Raised

$65M

Company Overview

Vicinitas Therapeutics is a biotechnology company that develops novel therapeutics for cancer and genetic disorders using its proprietary Deubiquitinase Targeting Chimeras (DUBTACs) protein stabilization platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

targeted protein stabilizationDUBTACdeubiquitinase targeting chimeraprotein degradationsmall molecule therapeuticsdrug discoverytargeted protein degradationTPDheterobifunctional moleculeshaploinsufficiencybiotech platformundruggable targetsprotein homeostasisprecision medicine

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Vicinitas Therapeutics Comparables

Compare Vicinitas Therapeutics with similar companies based on industry and business-model similarity.

Vicinitas Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Stablix
93%
Entact Bio
83%
General Proximity
73%

Vicinitas Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJul 28, 2022

Vicinitas Therapeutics Investors

Notable investors and investment history

Vicinitas Therapeutics investors
InvestorRounds
Andreessen HorowitzSeries A
Deerfield ManagementSeries A
GVSeries A
Droia VenturesSeries A
Berkeley Catalyst FundSeries A
The Mark Foundation for Cancer ResearchSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 28, 2022

    $65M round led by Andreessen Horowitz and Deerfield Management.

Vicinitas Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Vicinitas Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Vicinitas Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSouth San Francisco, California
Employee Range3
Year Founded2022
Last FundingJul 28, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?